Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 655-668 , December 2006

Radioimmunotherapy for B-cell non-Hodgkin lymphoma

  • Thomas E. Witzig, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 507 266 9276; Fax: +1 507 266 9277.

References 

  1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology. 1998;16:2825–2833
  2. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. Journal of Clinical Oncology. 2005;23:1103–1108
  3. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–106
  4. Hochster HS, Weller E, Gascoyne R, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma: results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood. 2005;106(11):349
  5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  6. Van Oers MHJ, Glabbeke MV, Tzeodorovic I, et al. Chimeric anti-CD20 monoclonal antibody (Rituximab;Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: final analysis of a phase III randomized intergroup clinical trial. Session Type: Oral Session Blood. 2005;106:[Abstract 353]
  7. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279–4284
  8. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine. 2002;346:235–242
  9. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP vs CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lympoma. Journal of Clinical Oncology. 2006;24(19):3121–3127
  10. Skvortsova I, Popper BA, Skvortsov S, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. Journal of Radiation Research. 2005;46:241–248
  11. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. Journal of Clinical Oncology. 2002;20:3545–3557
  12. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101:391–398
  13. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology. 2005;23:8447–8452
  14. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Journal of Nuclear Medicine. 2003;44:465–474
  15. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology. 1999;17:3793–3803
  16. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. Journal of Nuclear Medicine. 1998;39:21S–27S
  17. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. Journal of Nuclear Medicine. 1998;39:14S–20S
  18. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. The New England Journal of Medicine. 1993;329:459–465
  19. Wahl RL. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. Journal of Nuclear Medicine. 1998;39:1S
  20. Koral KF, Dewaraja Y, Li J, et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. Journal of Nuclear Medicine. 2003;44:457–464
  21. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research. 1996;2:457–470
  22. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology. 1996;14:1974–1981
  23. Stagg R, Wahl RL, Estes J, et al. Phase I/II study of iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma (NHL): final results. Proceedings of the American Society of Clinical Oncology. 1998;17:39a;[Abstract 150]
  24. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. Journal of Clinical Oncology. 2003;21:1263–1270
  25. Fehrenbacher L, Radford JA, Kaminski M, et al. Patient-specific dosing of Bexxar™ is associated with tolerable and predictable hematologic toxicity in patients with known hematologic risk factors. Proceedings of the American Society of Clinical Oncology. 2001;20:287a;[Abstract 1144]
  26. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:4336–4342
  27. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology. 2000;18:1316–1323
  28. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. The New England Journal of Medicine. 2005;352:441–449
  29. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology. 2001;19:3918–3928
  30. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576–4582
  31. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology. 1986;4:1470–1480
  32. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of 90Y-labeled ibritumomab tiuxetan (zevalin) radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology. 2002;20:2453–2463
  33. Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. Journal of Clinical Oncology. 1999;17:1244–1253
  34. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clinical Cancer Research. 2004;10:7792–7798
  35. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology. 2002;20:3262–3269
  36. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. Journal of Clinical Oncology. 2005;23:712–719
  37. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biotherapy & Radiopharmaceuticals. 2005;20:185–188
  38. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. Journal of Clinical Oncology. 2005;23:7565–7573
  39. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429–4431
  40. Morschhauser F, Huglo D, Martinelli G, et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood. 2004;110:[Abstract 130]
  41. Zelenetz A, Saleh M, Vose J, et al. Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab [Bexxar®]. Blood. 2002;100:[Abstract]
  42. Oki Y, Pro B, Delpassand E, et al. A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood. 2004;104:2632;[Abstract]
  43. Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. Journal of Clinical Oncology. 2002;20:3885–3890
  44. Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clinical Lymphoma. 2004;5:202–204
  45. Cooney J, Stiff P, Kaminski M. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab). Bone Marrow Transplantation. 2002;29:523–525
  46. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006;106:616–622
  47. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Journal of Clinical Oncology. 2005;23:7985–7993
  48. Wiseman G, Colgan J, Inwards D, et al. Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkins lymphoma (NHL): preliminary results. Blood. 2002;100:358a;[Abstract 1387]
  49. Wiseman G, Witzig T. Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkins lymphoma (NHL): preliminary results. Blood. 2002;100:358a;[Abstract 1387]
  50. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of Clinical Oncology. 2005;23:5696–5704
  51. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. [see comments] The New England Journal of Medicine. 1993;329:1219–1224
  52. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336–340
  53. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Journal of Clinical Oncology. 1998;16:3270–3278
  54. Press O, Eary J, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942
  55. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158–3162
  56. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896–2902
  57. Winter JN. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clincal Lymphoma. 2004;5:S22–S26
  58. Winter JN, Inwards D, Erwin W, et al. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results. Blood. 2002;100:411a;[Abstract 1597]
  59. Justice T, Martenson JA, Wiseman G, et al. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer. 2006;107(2):433–438

PII: S1521-6926(06)00033-8

doi: 10.1016/j.beha.2006.05.002

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 655-668 , December 2006

Article Tools